Combs Stephanie E, Gutwein Sybille, Thilmann Christoph, Debus Jürgen, Schulz-Ertner Daniela
Department of Radiation Oncology German Cancer Research Center (DKFZ), INF 280, Heidelberg, Germany.
Strahlenther Onkol. 2005 Dec;181(12):768-73. doi: 10.1007/s00066-005-1415-6.
To assess the effect of reirradiation in recurrent WHO grade III astrocytomas.
From January 1995 to July 2003, 40 patients with grade III gliomas were treated with fractionated stereotactic reirradiation at the time point of recurrence. Median size of planning target volume for reirradiation was 56.2 ml (range 25.1-296.2 ml). A median target total dose of 36 Gy (range 20-57.6 Gy) was applied using a median fractionation of 5 x 2 Gy/week with a 6-MeV linear accelerator.
Radiotherapy was well tolerated by all patients. No toxicities > CTC grade 2 developed. Median overall survival calculated from the time point of primary diagnosis was 48 months (range 7-180 months). The 5- and 10-year overall survival rates were 49.5% and 24.7%, respectively. From the time point of reirradiation, median survival was 16 months (range 1-98 months). Median progression-free survival from the time point of reirradiation was 8 months (range 1-72 months). No prognosticators for survival or progression-free survival after reirradiation could be identified.
Fractionated stereotactic radiotherapy is well tolerated and effective in patients with recurrent grade III astrocytomas.
评估再次放疗对复发性世界卫生组织III级星形细胞瘤的疗效。
1995年1月至2003年7月，40例III级胶质瘤患者在复发时接受了分次立体定向再次放疗。再次放疗计划靶体积的中位数为56.2毫升（范围25.1 - 296.2毫升）。使用6兆伏直线加速器，采用每周5次、每次2 Gy的分割方式，给予靶区总剂量中位数为36 Gy（范围20 - 57.6 Gy）。
所有患者对放疗耐受性良好。未出现大于CTC 2级的毒性反应。从初次诊断时间点计算的中位总生存期为48个月（范围7 - 180个月）。5年和10年总生存率分别为49.5%和24.7%。从再次放疗时间点起，中位生存期为16个月（范围1 - 98个月）。从再次放疗时间点起的中位无进展生存期为8个月（范围1 - 72个月）。未发现再次放疗后生存或无进展生存的预后因素。
分次立体定向放疗对复发性III级星形细胞瘤患者耐受性良好且有效。
Zotero 插件